Latham & Watkins Represents Purigen Biosystems in Its Acquisition by Bionano Genomics

Bionano Genomics, Inc. (NASDAQ: BNGO) has announced that it has entered into a definitive agreement to acquire Purigen Biosystems, Inc., a company that develops and commercializes automated nucleic acid extraction and purification solutions using proprietary isotachophoresis technology, which was licensed exclusively from Stanford and developed by Purigen.

Latham & Watkins LLP represented Purigen in the transaction with a corporate deal team led by Bay Area partner Mark Roeder, with associates Vidit Mehra, Rachelle Polsky, and Kevin Schunk. Advice was also provided on tax matters by Century City counsel Will Kessler, with San Diego associate Ryan Brenner; on intellectual property matters by Bay Area partner Jekkie Kim with associate Billy Wu; on data privacy matters by Houston counsel Robert Brown, with Bay Area/San Diego associate Jennifer Howes; and on benefits and compensation matters by Bay Area partner James Metz.